{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679852987136.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2169/internalmedicine.8618-16"}},{"identifier":{"@type":"PMID","@value":"29021477"}},{"identifier":{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/internalmedicine/56/24/56_8618-16/_pdf"}},{"identifier":{"@type":"NAID","@value":"130006250492"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2019144678"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@language":"en","@value":"Management of Osteoporosis in Chronic Kidney Disease"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"<p>Chronic kidney disease (CKD) patients with coexisting osteoporosis are becoming common. Many of the therapeutic agents used to treat osteoporosis are known to be affected by the renal function. It is generally thought that osteoporosis in G1 to G3 CKD patients can be treated as in non-CKD patients with osteoporosis. In stage 4 or more advanced CKD patients and CKD patients on dialysis with osteoporosis, however, bisphosphonates must be used with caution, bearing in mind the potential development of such disorders as adynamic bone disease. The use of vitamin D preparations in low doses is relatively safe. In postmenopausal women, raloxifene must be administered with caution. When using denosumab, the serum calcium concentrations should be monitored carefully to prevent the development of hypocalcemia, and active vitamin D preparations should be administered concomitantly. The present article provides an overview of the management of osteoporosis in CKD patients. </p>"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410282679852987136","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000377391800"}],"foaf:name":[{"@language":"en","@value":"Nitta Kosaku"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Kidney Center, Tokyo Women's Medical University, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679852987138","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000377391801"}],"foaf:name":[{"@language":"en","@value":"Yajima Aiji"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine, Kidney Center, Tokyo Women's Medical University, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276158172416","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"00246472"},{"@type":"NRID","@value":"1000000246472"},{"@type":"NRID","@value":"9000377391802"},{"@type":"NRID","@value":"9000256093872"}],"foaf:name":[{"@language":"en","@value":"Tsuchiya Ken"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Blood Purification, Kidney Center, Tokyo Women's Medical University, Japan"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09182918"},{"@type":"EISSN","@value":"13497235"}],"prism:publicationName":[{"@language":"en","@value":"Internal Medicine"},{"@language":"en","@value":"Intern. Med."}],"dc:publisher":[{"@language":"en","@value":"The Japanese Society of Internal Medicine"},{"@language":"ja","@value":"一般社団法人 日本内科学会"}],"prism:publicationDate":"2017","prism:volume":"56","prism:number":"24","prism:startingPage":"3271","prism:endingPage":"3276"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"https://www.jstage.jst.go.jp/article/internalmedicine/56/24/56_8618-16/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2019144678"}],"availableAt":"2017","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=CKD-MBD","dc:title":"CKD-MBD"},{"@id":"https://cir.nii.ac.jp/all?q=osteoporosis","dc:title":"osteoporosis"},{"@id":"https://cir.nii.ac.jp/all?q=bisphosphonate","dc:title":"bisphosphonate"},{"@id":"https://cir.nii.ac.jp/all?q=denosumab","dc:title":"denosumab"},{"@id":"https://cir.nii.ac.jp/all?q=SERM","dc:title":"SERM"},{"@id":"https://cir.nii.ac.jp/all?q=adynamic%20bone","dc:title":"adynamic bone"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000781968600320","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"17K09714"},{"@type":"JGN","@value":"JP17K09714"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17K09714/"}],"notation":[{"@language":"ja","@value":"繰り返し、軽度の腎障害の集積によるCKDの発症、重症化の機序の解明と治療介入"},{"@language":"en","@value":"Elucidation and therapeutic intervention of the mechanism of CKD onset and aggravation due to repeated and accumulated mild renal damages"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050298975368478592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Systemic amyloidosis with amyloid goiter: An autopsy report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145617697664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pathophysiology of Vascular Calcification"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618485794944","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bone Mineral Density and Fracture Risk in Older Individuals with CKD"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619692097152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparison of Fracture Risk Prediction among Individuals with Reduced and Normal Kidney Function"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565167561274368","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094596347648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of denosumab on fracture and bone mineral density by level of kidney function"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118763798912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567364384512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568677455488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519981364736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Increased risk of hip fracture among patients with end-stage renal disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521464054656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Determination of Bone Architecture and Strength in Men and Women with Stage 5 Chronic Kidney Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468676320640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Relationship between Moderate to Severe Kidney Disease and Hip Fracture in the United States"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469308047872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease — The DIVINE study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944283131136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Effect of Raloxifene Treatment in Postmenopausal Women with CKD"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418343259648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Eldecalcitol reduces osteoporotic fractures by unique mechanisms"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419685942144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A single-dose study of denosumab in patients with various degrees of renal impairment"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420879173248","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Osteoporosis Prevention, Diagnosis, and Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894181294592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Retracted: Bone Mineral Density Predicts Fractures in Chronic Kidney Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895773167872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Association of Kidney Function with Incident Hip Fracture in Older Adults"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370468016640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A review of minodronic acid hydrate for the treatment of osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370965344384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"How to predict and treat increased fracture risk in chronic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843809773568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319685656960","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Treatment of osteoporosis in renal insufficiency"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795660446592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269123458816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Renal Function and Risk of Hip and Vertebral Fractures in Older Women"}]},{"@id":"https://cir.nii.ac.jp/crid/2051151842050454144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evidence-based practice guideline for the treatment of CKD"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2003493129"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.8618-16"},{"@type":"PUBMED","@value":"29021477"},{"@type":"CIA","@value":"130006250492"},{"@type":"KAKEN","@value":"PRODUCT-21490447"},{"@type":"OPENAIRE","@value":"doi_dedup___::50ded10c335883002f6b555e25cb8351"},{"@type":"CROSSREF","@value":"10.1038/s41598-021-03966-6_references_DOI_NwfK7vXUVCu8KmXicEpoHEhxoZ0"},{"@type":"CROSSREF","@value":"10.1016/j.bbmt.2020.07.001_references_DOI_NwfK7vXUVCu8KmXicEpoHEhxoZ0"},{"@type":"CROSSREF","@value":"10.1016/j.legalmed.2022.102167_references_DOI_NwfK7vXUVCu8KmXicEpoHEhxoZ0"}]}